The PD1-resistant head and neck cancer market sales is predicted to increase at a compound annual growth rate (CAGR) of 12.5%, reaching a valuation of US$ 1.54 billion in 2023 and US$ 5 billion by 2033. The ageing population and initiatives from governmental and non-governmental groups like Support for People with Oral and PD1 Resistant …